Kesatuan Eropah - Czech - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Kesatuan Eropah - Czech - EMA (European Medicines Agency)

mylan ireland limited - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Kesatuan Eropah - Czech - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Kesatuan Eropah - Czech - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastická činidla - léčba rakoviny prsu, zvláštních forem rakoviny plic (nemalobuněčný karcinom plic), rakovina prostaty, rakovina žaludku nebo rakovina hlavy a krku.

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 9507 glimepirid - tableta - 2mg - glimepirid

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 9507 glimepirid - tableta - 3mg - glimepirid

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 9507 glimepirid - tableta - 4mg - glimepirid

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 18522 sevelamer-karbonÁt - potahovaná tableta - 800mg - sevelamer

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 17768 tikagrelor - potahovaná tableta - 60mg - tikagrelor

Republik Czech - Czech - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 17768 tikagrelor - potahovaná tableta - 90mg - tikagrelor